Recent advances in antileishmanial drug development
Antony J Davis1, Lukasz Kedzierski
1Division of Infection and Immunity, The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville 3050, Victoria, Australia.
Abstract:
Leishmania are protozoan parasites responsible for a spectrum of diseases collectively known as leishmaniasis. The disease is a significant health problem in many regions of the world and emerges as a serious co-infection in HIV-positive individuals. Current treatment of the disease is based on a limited number of chemotherapeutic agents which are rapidly becoming ineffective, and are characterized by high toxicity and cost. This review focuses on recent advances in antileishmanial drug development and improvements to current treatment options. Novel approaches currently used to identify leishmanicidal compounds as diverse as antimicrobial peptides and natural plant extracts are described in this review.
Related Concept Videos
Antiprotozoal Agents
Leishmaniasis
Anthelminthic Agents
Malaria
Drug Discovery: Overview
Pharmacogenomics: Identification of New Drug Targets


